Abstract:Persistent pulmonary hypertension of the newborn (PPHN) is a medical emergency in the neonatal period, which occurs due to failure of normal postnatal transition of fetal circulation. Despite availability of numerous treatment modalities, associated mortality and morbidity remain high. Therefore, awareness of predisposing conditions, and early diagnosis and management may help improving outcome in PPHN. To provide an overview of anatomic and functional anomalies of PPHN, and available treatment options with special focus on recent advances in the diagnosis and management of this potentially lethal illness. MEDLINE, EMBASE, The Cochrane Library, and Google Scholar databases were searched (inception until Nov-2012) using terms “ persistent pulmonary hypertension of newborn ” , “ hypoxemic respiratory failure ” , “ nitric oxide ” , “ sildenafil ” , “ milrinone ” and “ prostacyclin ” without any language restriction. www.clinicaltrials.gov website was searched for relevant ongoing trials. Additionally, manual review of article bibliographies was done for potentially relevant studies. Strategies for the management of PPHN are undergoing metamorphosis. Gentle ventilation and high-frequency ventilation have replaced prior hyperventilation strategy. Currently, iNO is the only FDA-approved selective pulmonary vasodilator for infants with hypoxemic respiratory failure / PPHN; however, it has poor / no response in upto 30% cases. Recent studies have provided evidences for the use of other therapeutic agents such as PDE-inhibitors, magnesium sulphate and prostacyclin analogues. Finally, recent laboratory studies have demonstrated the role of oxidant stress as well as potential use of free radical scavengers for example, superoxide dismutase and catalase in the management of PPHN. Assisted ventilation and pharmacologic manipulation are the mainstays of treatment of PPHN. Limited availability of the gold standard treatment option namely iNO, especially in resource-limited countries, leads to increasing use of alternative therapeutic options such as PDE-inhibitors (sildenafil and milrinone). However, as any single therapy can not be labelled as a magic bullet for PPHN, further clinical trials are required to demonstrate the efficacy and safety of available therapeutic options as well as to develop newer strategies targeted to the underlying pathophysiology. doi: http://dx.doi.org/10.4021/ijcp79w

Successful Management of the Persistent Pulmonary Hypertension of the Newborn with Transposition of the Great Arteries by Restricted Patency of the Ductus Arteriosus: A Simple and Rational Novel Strategy

The Progress in the Treatment of Persistent Pulmonary Hypertension in Neonatal

Prostaglandin E1 used as a pre-operative treatment for the neonates with transposition of great vessels with intact ventricular septum

Dextro-Transposition of the Great Arteries in a Neonate with Ventricular Septal Defect and Pulmonary Stenosis Complicated by Premature Closure of the Ductus Arteriosus and Possible Pathophysiology of Both Defects

Persistent pulmonary hypertension of the newborn infant (PPHN) due to premature closure of the ductus arteriosus (DA)

Inhaled Iloprost as a Rescue Therapy for Transposition of the Great Arteries With Persistent Pulmonary Hypertension of the Newborn

Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn

Persistent Pulmonary Hypertension of the Newborn: Recent Advances in the Management

Management of Persistent Pulmonary Hypertension in Newborns with ECMO Support: a Single Center's Experience

Persistent Pulmonary Hypertension of the Newborn with D-transposition of the Great Arteries: Management and Prognosis

Restoring Fetal Circulation as a Means of Bridging Treatment Prior to Surgical Repair of Anomalous Origin of the Right Pulmonary Artery from the Ascending Aorta with Persistent Pulmonary Hypertension of the Newborn

Advances in the Diagnosis and Management of Persistent Pulmonary Hypertension of the Newborn

Current Pharmaceutical Strategies in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN): A Comprehensive Review of Therapeutic Agents

The histological findings in transposition of the great artery with severe persistent pulmonary hypertension of the newborn

Patent Ductus Arteriosus of the Preterm Infant

Closing the Gap: Investigation of Various Approaches in the Management of Patent Ductus Arteriosus

Pathophysiology, Management, and Outcome of Persistent Pulmonary Hypertension of the Newborn: A Clinical Review

Pharmacologic therapy of persistent pulmonary hypertension of the newborn

Diagnosis and management of persistent pulmonary hypertension of the newborn

Personalized Evidence-Based Management of Patent Ductus Arteriosus in Preterm Infants

Comprehensive management for the improved outcome of persistent pulmonary hypertension of the newborn in a one-day-old baby girl: a case report